Summary
Highlights
Nattokinase is a supplement popular for its potential to improve circulation and break down blood clots. A recent study has uncovered that a characteristic present since birth might significantly impact its effectiveness, highlighting the need for personalized approaches to supplementation.
Nattokinase is an enzyme derived from fermented soybeans (natto). It works by directly cutting through fibrin, the protein backbone of blood clots, helping to dissolve them and restore blood flow. This specific action makes it a targeted approach to managing blood clots.
A February 2026 study published in Scientific Reports investigated whether nattokinase works uniformly across all individuals. Researchers analyzed nearly 2,000 blood samples, forming clots and measuring how long nattokinase took to dissolve them. They found a significant difference in dissolution times, primarily linked to blood type.
The study ranked blood types from fastest to slowest response to nattokinase: O was the fastest, followed by B, A, and then AB. O positive blood types showed the quickest clot dissolution, while AB negative showed the slowest. This difference is attributed to varying levels of von Willebrand factor, a protein that strengthens blood clots. Type O individuals naturally have lower levels of this factor, making their clots less dense and easier for nattokinase to break down.
Beyond blood type, the Rh factor also plays a role. Rh-positive individuals have an additional protein that appears to enhance nattokinase's efficiency. Furthermore, aging significantly affects the body's natural ability to dissolve clots, and this capacity declines from middle age onward. The study found the worst combination for nattokinase effectiveness was AB negative in the 66-70 age group, due to both genetic and age-related factors.
The study emphasizes that individual biology matters and that personalized prevention is crucial. It's important to know your blood type and consult with a healthcare provider who understands these biological nuances. For individuals not of O positive blood type, or those who are Rh negative and older, a conversation about personalized dosing or alternative strategies may be necessary. The speaker recommends starting with 2,000 fibrinolytic units (FU) for typical, healthy individuals, increasing gradually with monitoring if higher doses are considered, especially when on other blood thinners.